Being in the center of investors’ attention, Pharma stocks are gaining value more than other companies are.
FBS
In the virus-hit global economy, certain market segments have converted into a playground for fierce corporate competition.
That is definitely correct for the pharmaceutical sector with the public companies involved in developing the COVID-19 vaccine.
Being in the center of investors’ attention, they are gaining value more than other companies are. Those, which succeed with the vaccine, will surely see their stock price fly.
FBS offers you to fly with them: below is the list of the recently added pharma stocks - they give you a great opportunity to get extra profits while the rest of the world just starts awakening!
Moderna (MRNA)
Moderna is an American biotechnology company based in Cambridge. While this corporation specializes in transformative medicines based on messenger ribonucleic acid, its stock now specializes in showing an unseen velocity of value growth.
Challenging $30 per share when the virus hit, this stock has added more than 100% in value since then. If it grows another 100%, don’t say we didn’t tell you!
Somewhere on the way, it managed to make a leap of 400% up that value - now that you know what it is capable of, grab it while it is at $11!
Emergent (EBS)
Emergent BioSolutions is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.
It develops vaccines and antibody therapeutics for infectious diseases, opioid overdoses, and provides medical devices for biodefense purposes.
After it recovered 100% of its virus losses breaking $67, it went almost straight to the current $84 – a fusion of growth and consistency.
Pfizer (PFE)
One of the world's largest pharmaceutical companies, Pfizer has been in Dow Jones Industrial Average since 2004.
Its stock has been in decline since 2018 and currently trades at $38 after recovering from the drop to $28. Clearly, if it does well with the vaccine, the future may start shining again for Pfizer.
Sanofi (SNY)
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris. Sanofi engages in the research, production, and distribution of pharmaceutical products.
It was quick to recover almost all its losses and will surely be quick to climb higher if the vaccine is finally developed!
BioNTech (BNTX)
BioNTech SE provides biotechnological solutions. It is headquartered in Mainz, Germany. The Company develops various types of treatments for cancer patients and provides treatment worldwide.
Similar to Inovio, it made a vertical leap to +100% of its value and has full potential to repeat it – be there for it!
Novavax (NVAX)
Novavax is an American clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Uppsala, Sweden.
The company received an $89mln research grant from the Bill and Melinda Gates Foundation for the development of vaccines for maternal immunization – that is surely not for nothing! Trading currently at $25 per share, it was just 50% of it a month ago – don’t miss out on it!
Gilead (GILD)
Gilead Sciences is an American biopharmaceutical company headquartered in Foster City, California. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Disclaimer: The content of this article is sponsored and does not represent the opinions of Finance Magnates.
In the virus-hit global economy, certain market segments have converted into a playground for fierce corporate competition.
That is definitely correct for the pharmaceutical sector with the public companies involved in developing the COVID-19 vaccine.
Being in the center of investors’ attention, they are gaining value more than other companies are. Those, which succeed with the vaccine, will surely see their stock price fly.
FBS offers you to fly with them: below is the list of the recently added pharma stocks - they give you a great opportunity to get extra profits while the rest of the world just starts awakening!
Moderna (MRNA)
Moderna is an American biotechnology company based in Cambridge. While this corporation specializes in transformative medicines based on messenger ribonucleic acid, its stock now specializes in showing an unseen velocity of value growth.
Challenging $30 per share when the virus hit, this stock has added more than 100% in value since then. If it grows another 100%, don’t say we didn’t tell you!
Somewhere on the way, it managed to make a leap of 400% up that value - now that you know what it is capable of, grab it while it is at $11!
Emergent (EBS)
Emergent BioSolutions is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland.
It develops vaccines and antibody therapeutics for infectious diseases, opioid overdoses, and provides medical devices for biodefense purposes.
After it recovered 100% of its virus losses breaking $67, it went almost straight to the current $84 – a fusion of growth and consistency.
Pfizer (PFE)
One of the world's largest pharmaceutical companies, Pfizer has been in Dow Jones Industrial Average since 2004.
Its stock has been in decline since 2018 and currently trades at $38 after recovering from the drop to $28. Clearly, if it does well with the vaccine, the future may start shining again for Pfizer.
Sanofi (SNY)
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris. Sanofi engages in the research, production, and distribution of pharmaceutical products.
It was quick to recover almost all its losses and will surely be quick to climb higher if the vaccine is finally developed!
BioNTech (BNTX)
BioNTech SE provides biotechnological solutions. It is headquartered in Mainz, Germany. The Company develops various types of treatments for cancer patients and provides treatment worldwide.
Similar to Inovio, it made a vertical leap to +100% of its value and has full potential to repeat it – be there for it!
Novavax (NVAX)
Novavax is an American clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Uppsala, Sweden.
The company received an $89mln research grant from the Bill and Melinda Gates Foundation for the development of vaccines for maternal immunization – that is surely not for nothing! Trading currently at $25 per share, it was just 50% of it a month ago – don’t miss out on it!
Gilead (GILD)
Gilead Sciences is an American biopharmaceutical company headquartered in Foster City, California. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
XBO.com Partners with Bank Frick to Deliver Comprehensive Fiat On/Off-Ramp and Corporate Banking Services
Featured Videos
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.